2023年11月29日 · The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children.

Our treatment employs a multidisciplinary treatment plan that uses noninvasive, cost-effective oral appliance technology prescribed by trained dentists and medical professionals to treat …

2023年11月30日 · Vivos’ removable CARE oral appliances represent a non-invasive alternative to CPAP for patients with severe OSA. The appliances gradually reposition the hard and soft tissues that define a patient’s airway, thereby opening it up and optimizing its function and flow.

If you have been diagnosed with sleep apnea, you need to see a qualified medical doctor and/or a dentist with the appropriate training. If you have NOT yet been diagnosed with OSA, complete our self-assessment survey to be connected with a Vivos-trained provider in your area. Find out now if Vivos is right for you.

2023年12月1日 · 美国FDA已经批准Vivos公司的CARE (完全气道复位和或扩张)口腔矫治器，用于治疗成人重度阻塞性睡眠呼吸暂停 (OSA)。 Vivos的CARE矫治器包括下颌复位夜间矫治器，即mRNA口腔矫治器，和该设备的改良版本（称为mmRNA口腔…

Vivos CARE oral medical devices are a safe, comfortable, non-invasive, highly effective, and easy-to-use alternative that can significantly reduce or even eliminate your OSA symptoms.

2023年12月5日 · Recently, the FDA granted 510 (k) clearance to Vivos Therapeutics for its removable CARE (Complete Airway Repositioning and/or Expansion) oral appliances as a treatment option for patients with severe cases of obstructive sleep apnea (OSA).

AOM/DSS模型是目前使用最广泛的UC化学诱导模型，临床症状学、形态学及病理学观察证明，该模型与人类溃疡性结肠炎癌变过程极为相似。 AOM引起鸟嘌呤O6甲基化是诱导基因突变损伤最主要的原因，基因突变使细胞过度增殖…

2024年4月9日 · The Vivos Method is estimated to be indicated and potentially effective (within the scope of the FDA cleared uses) in approximately 80% of cases of OSA where patients are compliant with clinical...

2024年11月26日 · Vivos Therapeutics brings hope to the 90 million Americans affected by obstructive sleep apnea (OSA). Their FDA-cleared Vivos CARE oral devices offer a non-invasive alternative to CPAP therapy, with 97% of patients experiencing symptom relief.